Search the Epitope Variant and Escape Mutation Database

Help

Found 1 matching record:

Displaying record number 61555

HXB2 Location Pol(330-338) Pol Epitope Map
View variants at this location

NPEIVIYQY

`NPEIVIiQY`		diminished response; susceptible form
`NPEIVIvQY`		diminished response; susceptible form
`NPEIVIcQY`		diminished response; susceptible form

Epitope Name NY9

Species (MHC/HLA) human(B*3501)

Variant Details

Showing all: 3 variant(s).

Variant ID.	`3962`
Epitope Seq.	`NPEIVIYQY`
Variant Seq.	`NPEIVIiQY`
Mutations	Y/I
Epitope Location	Y7I
HXB2 Location	Y336I
Mutation Type	DR: diminished response SF: susceptible form
Epitope Subtype	CRF01_AE
Variant Subtype	CRF01_AE
Method	CD8 T-cell Elispot - IFNy, Chromium-release assay, Intracellular cytokine staining
Note	Subtype A/E's NY9-3E mutant, NY9-3E7I, was cross-recognized by CTL from 3 Japanese A/E-infected subjects (KI-667, KI-805, KI-1124). NY9-3E-specific CTL from KI-667 recognized NY9-3E7I peptide as well as they did WT NY9-3E, but KI-667's CTL had lower cytotoxic ability against cells infected with mutant 7I. NY9-3E-specific CTL from KI-805 recognized NY9-3E7I peptide more strongly than WT but 7I-infected cells were recognized similarly to WT. Affinity of NY9-3E7I was greater for HLA-B*3501 when compared to WT NY9-3E.

Variant ID.	`3963`
Epitope Seq.	`NPEIVIYQY`
Variant Seq.	`NPEIVIvQY`
Mutations	Y/V
Epitope Location	Y7V
HXB2 Location	Y336V
Mutation Type	DR: diminished response SF: susceptible form
Epitope Subtype	CRF01_AE
Variant Subtype	CRF01_AE
Method	CD8 T-cell Elispot - IFNy, Chromium-release assay, Intracellular cytokine staining
Note	Subtype A/E's NY9-3E mutant, NY9-3E7V, was cross-recognized by CTL from 3 Japanese A/E-infected subjects (KI-667, KI-805, KI-1124). NY9-3E-specific CTL from KI-667 recognized NY9-3E7V peptide more weakly than WT NY9-3E, and KI-667's CTL had lower cytotoxic ability against cells infected with mutant 7V. NY9-3E-specific CTL from KI-805 recognized NY9-3E7V peptide as well as 7V-infected cells more strongly than WT . Affinity of NY9-3E7V was greater for HLA-B*3501 when compared to WT NY9-3E.

Variant ID.	`3964`
Epitope Seq.	`NPEIVIYQY`
Variant Seq.	`NPEIVIcQY`
Mutations	Y/C
Epitope Location	Y7C
HXB2 Location	Y336C
Mutation Type	DR: diminished response SF: susceptible form
Epitope Subtype	CRF01_AE
Variant Subtype	CRF01_AE
Method	CD8 T-cell Elispot - IFNy, Chromium-release assay, Intracellular cytokine staining
Note	Subtype A/E's NY9-3E mutant, NY9-3E7C, was cross-recognized by CTL from 3 Japanese A/E-infected subjects (KI-667, KI-805, KI-1124). NY9-3E-specific CTL from KI-667 recognized NY9-3E7C peptide more weakly than WT NY9-3E, and KI-667's CTL had lower cytotoxic ability against cells infected with mutant 7C. NY9-3E-specific CTL from KI-805 recognized NY9-3E7C peptide as well as 7C-infected cells more weakly than WT . Affinity of NY9-3E7C was greater for HLA-B*3501 when compared to WT NY9-3E.

References

Kuse2015 Nozomi Kuse, Mohammad Arif Rahman, Hayato Murakoshi, Giang Van Tran, Takayuki Chikata, Madoka Koyanagi, Kinh Van Nguyen, Hiroyuki Gatanaga, Shinichi Oka, and Masafumi Takiguchi. Different Effects of Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations on Cytotoxic T Lymphocyte Recognition between HIV-1 Subtype B and Subtype A/E Infections. J. Virol., 89(14):7363-7372, Jul 2015. PubMed ID: 25972553. Show all entries for this paper.